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eral blood stem cell (PBSC) transplantation (HCT) to
cure leukemia through a graft-versus-leukemia (GVL)
effect represents a conspicuous example of the capacity
of the human immune system to recognize and destroy
tumors. The GVL effect is mediated in large part by
donor T cells that recognize minor histocompatibility
(H) antigens, which are derived from endogenous
proteins in recipient cells that differ from the donor be-
cause of genetic polymorphism and provide distinct
HLA binding peptides. The potency of theGVL effect
is illustrated by the use of reduced-intensity condition-
ing (RIC) regimens that alone are not myeloablative
and only modestly reduce the tumor burden, but can
induce durable remissions in patients particularly
those with indolent malignancies. We have examined
alloreactive T cell responses in patients with CLL after
nonmyeloablative HCT and found that patients that
experience sustained tumor regression develop CD81
and CD41 T cell responses directed against multiple
minor H antigens expressed by CLL. By contrast, pa-
tients with progressive CLL after HCT fail to develop
T cell responses that recognize leukemic cells, even
though they may develop graft-versus-host disease
(GVHD). This suggests that HCT fails to eradicate
CLL in these patients because alloreactivity is focused
on minor H antigens that are not expressed by tumor
cells, although intrinsic resistance mechanisms of
tumor cells to immune attack may play a role in some
patients.
The existence of a GVL effect is incontrovertible,
but segregating GVL from GVHD and manipulating
GVL activity to improve transplant outcome in pa-
tients with advanced leukemia have yet to be routinely
achieved. An increasing number of minor H antigens
recognized by class I HLA-restricted CD81 T cells
are being characterized at the molecular level, driven
both by new techniques for isolating alloreactive T
cells from HLA identical siblings and by improved2methods for mapping and locating polymorphic genes
that encode minor H antigens. The subset of minor H
antigens that are selectively expressed by leukemic
progenitor cells represent the most attractive targets
to promote a GVL effect without GVHD, and assem-
bling a library of suitable antigens to enable therapy of
most HCT recipients is gradually being accom-
plished. However, allogeneic HCT using unmodified
PBSC grafts represents a challenging setting in which
to execute specific immunotherapy, because of the
confounding effects of immunosuppressive drugs and
GVHD. Research in model systems has refined our
view of GVHD pathogenesis, and identified novel
approaches to HCT that diminish GVHD including
the use of stem cell grafts that are depleted of
CD62L1 naı¨ve T cells. If this approach can be trans-
lated to human HCT, this would create an improved
platform to implement immunotherapy that could
target alloreactivity selectively to leukemic cells.
The adoptive transfer of T cell clones specific for
individual minor H antigens is an elegant strategy to
augment a GVL effect, and initial studies of this
approach in patients with acute leukemia show that
donor T cell clones can be transferred safely, migrate
to sites of leukemia, and mediate antitumor effects in
a subset of patients. However, like many efforts at can-
cer immunotherapy in humans, a limitation of this
strategy is the frequent failure of transferred T cells
to persist long term after infusion. The T lymphocyte
pool from which T cells for adoptive immunotherapy
can be isolated contains naı¨ve (TN), central memory
(TCM), and effector memory (TEM) subsets that differ
in phenotype, function, and homing. We have evalu-
ated the intrinsic capacity of antigen-specific CD81
T cell clones derived from TCM and TEM subsets to
persist in vivo in a nonhuman primate model. Effector
T cell clones derived from TCM but not TEM precur-
sors are similar in phenotype, cytolytic function, pro-
liferative capacity, and telomere length. However,
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in vivo, reacquire phenotypic and functional properties
of memory cells, and occupy memory T cell niches.
These results demonstrate that clonally derived effec-
tor cells isolated from central memory T cells are
distinct from those derived from effector memory T
cells, and retain an intrinsic capacity that enables
them to survive after adoptive transfer and revert to
the memory pool. These results have implications for
T cell therapy to augment GVL activity because the
origin of minor H antigen-specific or other leukemia
reactive T cells that are isolated ex vivo may differdepending on how they are derived. If minor H anti-
gen-specific T cells are isolated from donor blood,
they may be derived from the naı¨ve T cell subset; if
they are isolated from the patients posttransplant,
they may be derived from 1 of the memory subsets.
Thus, alternative approaches for generating T cells
to promote a GVL response may need to be developed
including the introduction in to TCM precursors of
genes encoding antigen-specific T cell receptors or
chimeric immunoreceptors that target tumor cell
surface molecules to ensure the effector cells that are
generated are capable of persisting in vivo.
